![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/SUVENPHAR.png)
Share the post "Suven Pharmaceuticals ‘s Q3 2024-25 Latest News: Revenue Rises by 39.73% YoY"
Highlights
🔹 The presented financial data is Consolidated to provide a comprehensive overview of the company performance. 🔹 Sales over the Year and quarter: The company experienced a substantial growth of 39.73 % in the past year, substantial increase in net sales/revenue by 19.18 %. 🔹 Income over the Year and quarter: There has been either a marginal increase or a decline in other income over the past year which is 9.52 %. Marginal increase in other income during this quarter, up by 11.26%. 🔹 Profit over the Year and quarter: Significant improvement in profitability for Suven Pharmaceuticals Limited. Notable increase of 78.15 % in net profit Year to Year, Suven Pharmaceuticals Limited’s profitability increased by 1.6 % in this quarter. 🔹 EPS over the Year and quarter: EPS increased by 77.17 % Year to Year. EPS increased by 0.93 % in previous quarter. Positive impact on shareholders.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 219.82 Cr | Rs. 257.72 Cr | Rs. 307.15 Cr | + 19.18 % | + 39.73 % |
| Expenses | Rs. 154.67 Cr | Rs. 153.71 Cr | Rs. 189.45 Cr | + 23.25 % | + 22.49 % |
| Operating Profit | Rs. 65.15 Cr | Rs. 104.01 Cr | Rs. 117.7 Cr | + 13.16 % | + 80.66 % |
| OPM % | 29.64 % | 40.36 % | 38.32 % | -2.04 % | + 8.68 % |
| Other Income | Rs. 14.345 Cr | Rs. 14.12 Cr | Rs. 15.71 Cr | + 11.26 % | + 9.52 % |
| Interest | Rs. 1.27 Cr | Rs. 1.67 Cr | Rs. 3.33 Cr | + 99.4 % | + 162.2 % |
| Depreciation | Rs. 12.75 Cr | Rs. 16.96 Cr | Rs. 20.35 Cr | + 19.99 % | + 59.61 % |
| Profit before tax | Rs. 65.48 Cr | Rs. 99.5 Cr | Rs. 109.73 Cr | + 10.28 % | + 67.58 % |
| Tax % | 28.59 % | 17.61 % | 24.1 % | + 6.49 % | -4.49 % |
| Net Profit | Rs. 46.75 Cr | Rs. 81.98 Cr | Rs. 83.29 Cr | + 1.6 % | + 78.16 % |
| EPS in Rs | Rs. 1.84 | Rs. 3.21 | Rs. 3.23 | + 0.62 % | + 75.54 % |
Today, we’re looking at Suven Pharmaceuticals Limited’s financial performance for the Q3(Dec 2024-25).Starting with the top line, the company reported a robust year-over-year sales growth of 39.73 %. However, it did see a marginal increase of 19.18 % from the previous quarter. Expenses ticked up slightly by 23.25 % quarter-on-quarter, aligning with the annual rise of 22.49 %. Operating profit, while up 80.66 % compared to last year, faced a quarter-on-quarter increase of 13.16 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 8.68 %, but a shrinkage of -2.04 % sequentially. Other income rose by 11.26 % compared to the last quarter, despite an annual growth of 9.52 %. Interest expenses surged remarkably by 99.4 % from the previous quarter, yet the year-over-year increase remains at a moderate 162.2 %. Depreciation costs climbed by 19.99 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 59.61 %. Profit before tax grew annually by 67.58 % but saw an increase from the preceding quarter by 10.28 %.
Tax expenses as a percentage of profits decreased slightly by -4.49 % compared to last year, with a more notable quarter-on-quarter increase of 6.49 %. Net profit rose by 78.16 % year-on-year but experienced a 1.6 % expansion from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 75.54 % but a quarterly rise of 0.62 %. In summary, Suven Pharmaceuticals Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 219.82 Cr | Rs. 257.72 Cr | Rs. 307.15 Cr | + 19.18 % | + 39.73 % |
| Expenses | Rs. 154.67 Cr | Rs. 153.71 Cr | Rs. 189.45 Cr | + 23.25 % | + 22.49 % |
| Operating Profit | Rs. 65.15 Cr | Rs. 104.01 Cr | Rs. 117.7 Cr | + 13.16 % | + 80.66 % |
| Net Profit | Rs. 46.75 Cr | Rs. 81.98 Cr | Rs. 83.29 Cr | + 1.6 % | + 78.16 % |
| EPS in Rs | Rs. 1.84 | Rs. 3.21 | Rs. 3.23 | + 0.62 % | + 75.54 % |
In reviewing Suven Pharmaceuticals Limited’s 2024-25(Q3) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 39.73 % year-on-year growth, however, there was a minor increase of 19.18 % from the previous quarter. Expenses rose by 22.49 % compared to the previous year, with a 23.25 % increase quarter-on-quarter. Operating Profit surged by 80.66 % annually, and saw a 13.16 % increase from the last quarter.
Net Profit showed yearly increase of 78.16 %, and experienced a 1.6 % increase from the previous quarter. Earnings Per Share (EPS) rose by 75.54 % annually, however rose by 0.62 % compared to the last quarter. In essence, while Suven Pharmaceuticals Limited exhibits strong annual growth indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.
![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/BIHSPONG.png)